Citations

Clear

511 citation(s) found for "Seth, N".

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.
Agulnik, Mark , Okuno, Scott H. , Tine, Brian Andrew Van, Weiss, Mia C. , Viveiros, Pedro, Schulte, Brian , Frankel, Paul , Attia, Steven , Charlson, John A. , Yoon, Janet, Frankel, Paul , Pollack, Seth M. , Hirbe, Angela C. , Siontis, Brittany L. , Milhem, Mohammed , Monga, Varun , Robinson, Steven I.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 11505-11505

10.1200/jco.2023.41.16_suppl.11505 Get It

11505 Background: Potentiation of chemotherapy, without increased toxicity, to improve outcome is an area of interest. Preclinical and clinical evidence shows simultaneous utilization of antiangiogenic agents and chemotherapy have a synergistic effect. We hypothesized that the dual targeting of VEGF and c-MET pathways with cabozantinib (CAB) would result in clinical benefit for patients with soft tissue sarcoma (STS) when combined with temozolomide (TMZ), an alkylating agent. Utilization of CAB/TMZ is anticipated to produce a synergistic antitumor effect worthwhile to explore in STS. Methods: A multicenter phase II study of CAB/TMZ in patients with unresectable/metastatic leiomyosarcoma (LMS) and other STS was conducted by the Midwest Sarcoma Trials Partnership. Age ≥ 18, adequate performance status, organ function, measurable disease (RECIST 1.1), and 0-5 prior chemotherapy regimens were required. CAB 40 mg PO daily plus TMZ 150-200 mg/m2 PO 1-5 days were given in 28-day cycles until disease progression or unacceptable toxicity. Patients enrolled in 2 cohorts: 1. Uterine and non-uterine LMS 2. Other STS. The first 14 subjects to be enrolled in the study in either cohort served as a safety lead in. The primary endpoint was progression-free rate (PFR) at 12 weeks for cohort 1. Secondary endpoints include overall response rate (ORR), clinical benefit rate, median progression-free survival (PFS), overall survival, and safety and tolerability. The exploratory endpoint was to estimate the correlation of PFR and OS to expression levels of VEGF, amongst others. A Simon 2-stage design was used. Results: A total of 42 patients were enrolled in Cohort 1, and 30 in Cohort 2, across 5 sites. For Cohort 1, median age was 59 years (range 35-86), 85.7% were non-Hispanic, 73.8% were female, 61.9% had ECOG of 0. The PFR at 12 weeks was 45.9% (for 37 evaluable patient) with a median PFS of 6.4 months (95% CI 4.6-6.7). Five PR were observed for an ORR of 13.5%. For Cohort 2, median age was 63 (20-86), 83.3% were non-Hispanic, 36.7% were female, 53.3% had ECOG of 0. The PFR at 12 weeks was 50% (for 28 evaluable patients) with a median PFS of 3.2 months (95% CI 1.4-4.6). One PR was observed. Reported grade 3-4 adverse events attributed to one or both intervention drugs affecting ≥10% of patients (n = 70) included hypertension (10%), decreased neutrophils (18.7%), decreased platelets (31%). Conclusions: The combination therapy of CAB/TMZ in patients with unresectable or metastatic LMS exceeded its primary endpoint with a PFR at 12 weeks > 39%. The PFS of 6.4 months in Cohort 1 exceeds rates achieved with second line tyrosine kinase inhibitors (TKIs) and alkylators in LMS patients. Treatment was feasible and did not reveal any previously unreported toxicities. The combination with CAB with TMZ demonstrated meaningful clinical benefit and is worth further exploration in LMS. Clinical trial information: NCT04200443 .
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
Phillips, Ryan , Proudfoot, James A. , Liu, Yang , Feng, Felix Y. , Simko, Jeff, Pollack, Alan , Patel, Samir , Straza, Michael , Shah, Amit B. , Rodgers, Joseph P., Davicioni, Elai , Spratt, Daniel E. , Den, Robert B. , Rosenthal, Seth A. , Sartor, Oliver , Sweeney, Christopher J. , Attard, Gerhardt , Efstathiou, Jason A. , Sandler, Howard M. , Tran, Phuoc T

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 5094-5094

10.1200/jco.2023.41.16_suppl.5094 Get It

5094 Background: In prior studies, basal vs. luminal differentiation portends differential response to a) androgen suppression (AS) duration for high-risk prostate cancer (PCa) (NRG-GU-TS006) and b) docetaxel chemotherapy (CT) and AS for metastatic hormone-sensitive disease (CHAARTED). In NRG-GU-TS006, basal tumors appeared to benefit the most from longer duration of AS while those with luminal subtype did not whereas, in CHAARTED, luminal subtype had greater benefit from addition of CT. Herein, we examined basal-luminal subtyping to predict differential response to the addition of CT in the setting of high-risk PCa treated with AS and definitive radiotherapy (AS + RT) in NRG/RTOG 0521. Methods: Per pre-specified and approved NCI analysis plan (Navigator #1061), we obtained available NRG biobank biopsy specimens from patients enrolled on the NRG/RTOG 0521 phase III trial, which randomized patients to AS + RT +/- CT. The highest-grade tumors were profiled on clinical-grade whole-transcriptome arrays (Veracyte, San Diego, CA). Basal-luminal subtypes were generated using a 215-gene PCa subtyping classifier (PSC), a second generation PAM50 basal-luminal model. Treatment effects in Luminal Proliferating (LP) and non-LP subtypes were examined with Cox (for overall survival, OS, and metastasis-free survival, MFS) and Fine & Gray (for distant metastasis, DM) multivariable (MVA) models adjusted for age and trial risk stratification, as well as with restricted mean survival times (RMST). Results: Of 183 samples available for analysis (91 from control and 92 from the CT arm), 52 (28%) were classified as LP subtype. Median follow-up for OS was 9.9 years. No significant differences in clinical or pathological variables were observed between LP and non-LP subtypes. In MVA, we did not detect any significant LP subtype-by-CT treatment interaction but observed evidence of non-proportional hazards (Grambsch-Therneau test, p<0.05). In unselected patients, 5- and 10-year RMST difference between the arms was 0.9 (95% CI [-1.5, 3.4], p=0.46) and 5.7 (95% CI [-2.5, 13.9], p=0.17) months of OS. Stratifying by tumor subtype, at 5 years the RMST difference in months was 3.8 (95% CI [0.3, 7.2], p=0.03) for LP and -0.2 ([-3.4, 2.9], p=0.89) for non-LP. The RMST difference in months at 10-years was 13.7 (95% CI [-0.2, 27.5], p=0.053) for LP and 2.5 ([-7.6, 12.5], p=0.63) for non-LP. Conclusions: In pre-treatment biopsy samples from a Phase 3 trial cohort of localized high-risk men, luminal-basal subtyping of tumors demonstrated differential response to docetaxel CT. Similar to results from the CHAARTED trial of metastatic disease, LP tumors may derive greater benefit from addition of CT. Validation of these findings may enable effective earlier use of CT in men with PCa.
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.
Ganjoo, Kristen N. , Araujo, Dejka M. , Razak, Albiruni Ryan Abdul, Cesne, Axel Le , Schuetze, Scott M. , Wagner, Michael J. , Attia, Steven , Forcade, Édouard , Druta, Mihaela , Bai, Jane P. F., Lunt, Colin, Sun, Amy , Yule, Murray, McAlpine, Cheryl, Williams, Dennis, Tine, Brian Andrew Van, D'Angelo, Sandra P , Blay, Jean‐Yves , Valverde, Claudia María , Pollack, Seth M.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e14531-e14531

10.1200/jco.2023.41.16_suppl.e14531 Get It

e14531 Background: Afami-cel is an autologous, T-cell receptor T-cell therapy engineered to target melanoma-associated antigen A4 (MAGE-A4) in human leukocyte antigen (HLA) A*02–eligible patients (pts) with advanced solid tumors. SPEARHEAD-1 (NCT04044768) is a Phase 2, two cohort, open-label trial to evaluate the efficacy and safety of afami-cel in pretreated pts with advanced/metastatic synovial sarcoma or myxoid/round cell liposarcoma. Here we report data on cytokine release syndrome (CRS) in the pts with advanced synovial sarcoma treated with afami-cel across Cohort 1 and Cohort 2. Methods: Eligible pts had advanced synovial sarcoma and were HLA-A*02 positive with MAGE-A4–positive tumors. Pts received afami-cel after lymphodepleting chemotherapy containing fludarabine and cyclophosphamide. Tocilizumab administration was permitted for Grade 1 CRS if symptoms persisted for ≥ 24 hours or if the pt had co-morbidities, and for Grade ≥2 CRS. Results: As of August 29, 2022, 72 pts with synovial sarcoma received afami-cel (n = 44 Cohort 1; n = 28 Cohort 2). Afami-cel dose range was 1.92–10.00×109 transduced T-cells. The median age was 39.5 years (range: 16–73 years), 47.2% of pts were female, 88.3% of pts were white, and tumor MAGE-A4 expression H-score was 244.5 (range: 66–300). CRS occurred in 72.2% of the pts with synovial sarcoma receiving afami-cel, including Grade 1 in 50% (36/72), Grade 2 in 20.8% (15/72), and Grade 3 in 1.4% (1/72) of pts as per American Society for Transplantation and Cellular Therapy grading. The median time to onset was 2.5 days (range: 1–5 days), and the median time to resolution was 3 days (range: 1 to 14 days). Twenty-seven of 72 (37.5%) pts received at least one dose of tocilizumab. Consistent with expectations, higher serum IL-6 levels were associated with CRS events and the indicated use of tocilizumab for management. RECIST v1.1 responses were observed in pts with and without CRS. Correlation of clinical factors and CRS with response will be presented. Conclusions: CRS was common after afami-cel administration but was mostly low grade. Administration of tocilizumab in SPEARHEAD-1 was effective in the management of CRS. Clinical trial information: NCT04044768 .
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database
Ahn, Joseph , Wi, Chung‐Il , Buryska, Seth , Sivasubramaniam, Priyadharshini , Harmsen, William S. , Kamath, Patrick S. , Juhn, Young J. , Shah, Vijay H. , Ahn, Joseph C , Simonetto, Douglas A , Juhn, Y J , Wi, Chung-Ii , Simonetto, Douglas A.

Mayo Clinic

Hepatology Communications | May 31, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1097/hc9.0000000000000160 | PMID 37255371 Get It

Background: Alcohol-associated hepatitis (AH) is among the deadliest liver diseases, but its incidence is poorly defined. The aim of our study was to define the incidence of AH meeting the National Institute on Alcohol Abuse and Alcoholism criteria and to identify risk factors for AH. Methods: We conducted a retrospective cohort study using the Rochester epidemiology project database on adult patients hospitalized with AH between January 1, 2000 and December 31, 2018. Patients were screened using ICD-9 codes and then included if they met the National Institute on Alcohol Abuse and Alcoholism criteria on manual chart review. Baseline demographics, comorbidities, access to care, liver-related complications, and outcomes were obtained. The HOUsing-based index of SocioEconomic status index was used to measure socioeconomic status. Incidence rates were calculated in cases per 100,000 person-years of follow-up. Results: Among 204 patients, the cumulative AH incidence was 6.8 per 100,000 person-years. Between 2000–2004 and 2015–2018, AH incidence among males increased from 8.4 to 14.7 per 100,000 py, whereas AH incidence among females increased by 7-fold from 0.8 to 5.9 per 100,000 py. Such increases among females were accompanied by increases in comorbid depression and anxiety. The proportion of patients with AH in the lower socioeconomic status quartiles increased from 62.9% between 2000 and 2004 to 73.3% between 2015 and 2019. Conclusions: The incidence of AH is increasing rapidly, especially among females and individuals of lower socioeconomic status. There are areas of unmet need in preventative measures and treatments for comorbid psychiatric disorders in patients at high risk of AH.
Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive Pulmonary Disease
Díaz, Alejandro A. , Orejas, J. , Grumley, Scott , Nath, Hrudaya , Wang, Wei , Yen, Andrew , Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Sonavane, Sushilkumar K. , Washko, George R. , Estépar, Raúl San Jośe , San Jose Estepar, Raul , Diaz, Alejandro A , Dolliver, Wojciech Remington , Yen, Andrew, Aziz, Muhammad Usman , Estépar, R. San José , Kim, Victor, Make, Barry J. , Han, MeiLan King , Cho, Michael H.

Mayo Clinic

JAMA | May 21, 2023 | Volume: 329 | Issue: 21 | Pages: 1832

10.1001/jama.2023.2065 | PMID 37210745 Get It

Importance Airway mucus plugs are common in patients with chronic obstructive pulmonary disease (COPD); however, the association of airway mucus plugging and mortality in patients with COPD is unknown. Objective To determine whether airway mucus plugs identified on chest computed tomography (CT) were associated with increased all-cause mortality. Design, Setting, and Participants Observational retrospective analysis of prospectively collected data of patients with a diagnosis of COPD in the Genetic Epidemiology of COPD cohort. Participants were non-Hispanic Black or White individuals, aged 45 to 80 years, who smoked at least 10 pack-years. Participants were enrolled at 21 centers across the US between November 2007 and April 2011 and were followed up through August 31, 2022. Exposures Mucus plugs that completely occluded airways on chest CT scans, identified in medium- to large-sized airways (ie, approximately 2- to 10-mm lumen diameter) and categorized as affecting 0, 1 to 2, or 3 or more lung segments. Main Outcomes and Measures The primary outcome was all-cause mortality, assessed with proportional hazard regression analysis. Models were adjusted for age, sex, race and ethnicity, body mass index, pack-years smoked, current smoking status, forced expiratory volume in the first second of expiration, and CT measures of emphysema and airway disease. Results Among the 4483 participants with COPD, 4363 were included in the primary analysis (median age, 63 years [IQR, 57-70 years]; 44% were women). A total of 2585 (59.3%), 953 (21.8%), and 825 (18.9%) participants had mucus plugs in 0, 1 to 2, and 3 or more lung segments, respectively. During a median 9.5-year follow-up, 1769 participants (40.6%) died. The mortality rates were 34.0% (95% CI, 32.2%-35.8%), 46.7% (95% CI, 43.5%-49.9%), and 54.1% (95% CI, 50.7%-57.4%) in participants who had mucus plugs in 0, 1 to 2, and 3 or more lung segments, respectively. The presence of mucus plugs in 1 to 2 vs 0 and 3 or more vs 0 lung segments was associated with an adjusted hazard ratio of death of 1.15 (95% CI, 1.02-1.29) and 1.24 (95% CI, 1.10-1.41), respectively. Conclusions and Relevance In participants with COPD, the presence of mucus plugs that obstructed medium- to large-sized airways was associated with higher all-cause mortality compared with patients without mucus plugging on chest CT scans.
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody
Murray, David , Buadi, Francis K. , Gertz, Morie A. , Yadav, Udit , Kumar, Shaji , Gonsalves, Wilson I. , Seth, Abhishek, Buadi, Francis K , Gertz, Morie A , Kumar, Shaji K , Gonsalves, Wilson , Seth, Abhishek

Mayo Clinic

European Journal of Haematology | May 20, 2023 | Volume: 111 | Issue: 2 | Pages: 318-321

10.1111/ejh.14008 | PMID 37209032 Get It

AbstractDaratumumab is an anti‐CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher‐than‐expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.
Interim Results of a Phase 1/2 Open‐Label Study of INO ‐3107 for HPV ‐6 and/or
Mau, Ted , Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Lott, David G. , Paniello, Randal C. , Pransky, Seth M. , Howard, Tamara , Dallas, Michael, Patel, Aditya , Morrow, Matthew P. , Skolnik, Jeffrey M. , Best, Simon R , Friedman, Aaron D , Lott, David G , Paniello, Randal C , Mau, Ted , Amin, Milan R , Klein, Adam M. , Saba, Nabil F. , Howard, Tamara, Dallas, Michael J.

Mayo Clinic

The Laryngoscope | May 19, 2023 | Volume: 133 | Issue: 11 | Pages: 3087-3093

10.1002/lary.30749 | PMID 37204106 Get It

Objective To evaluate the safety, immunogenicity, and efficacy of INO‐3107, a DNA immunotherapy designed to elicit targeted T‐cell responses against human papillomavirus (HPV) types 6 and 11, in adult patients with recurrent respiratory papillomatosis (RRP; NCT04398433). Methods Eligible patients required ≥2 surgical interventions for RRP in the year preceding dosing. INO‐3107 was administered by intramuscular (IM) injection followed by electroporation (EP) on weeks 0, 3, 6, and 9. Patients underwent surgical debulking within 14 days prior to first dose, with office laryngoscopy and staging at screening and weeks 6, 11, 26, and 52. Primary endpoint was safety and tolerability, as assessed by treatment‐emergent adverse events (TEAEs). Secondary endpoints included frequency of surgical interventions post‐INO‐3107 and cellular immune responses. Results An initial cohort of 21 patients was enrolled between October 2020 and August 2021. Fifteen (71.4%) patients had ≥1 TEAE; 11 (52.4%) were Grade 1, and 3 (14.3%) were Grade 3 (none treatment related). The most frequently reported TEAE was injection site or procedural pain ( n = 8; 38.1%). Sixteen (76.2%) patients had fewer surgical interventions in the year following INO‐3107 administration, with a median decrease of 3 interventions versus the preceding year. The RRP severity score, modified by Pransky, showed improvement from baseline to week 52. INO‐3107 induced durable cellular responses against HPV‐6 and HPV‐11, with an increase in activated CD4 and CD8 T cells and CD8 cells with lytic potential. Conclusion The data suggest that INO‐3107 administered by IM/EP is tolerable and immunogenic and provides clinical benefit to adults with RRP. Level of Evidence 3 Laryngoscope , 133:3087–3093, 2023
J‐Difference editing (MEGA) of lactate in the human brain at 3T
Robison, Ryan K. , Haynes, Justin R., Ganji, Sandeep , Nockowski, Charles P., Kovács, Zoltán , Morgan, Victoria L. , Smith, Seth A., Thompson, Reid C., Gore, John C. , Choi, Changho , Ganji, Sandeep K, Choi, Changho , Morgan, Victoria L , Ganji, Sandeep K , Pham, Wellington N. , Omary, Reed A.

Mayo Clinic

Magnetic Resonance in Medicine | May 8, 2023 | Volume: 90 | Issue: 3 | Pages: 852-862

10.1002/mrm.29693 | PMID 37154389 Get It

PurposeThe need to detect and quantify brain lactate accurately by MRS has stimulated the development of editing sequences based on J coupling effects. In J‐difference editing of lactate, threonine can be co‐edited and it contaminates lactate estimates due to the spectral proximity of the coupling partners of their methyl protons. We therefore implemented narrow‐band editing 180° pulses (E180) in MEGA‐PRESS acquisitions to resolve separately the 1.3‐ppm resonances of lactate and threonine.MethodsTwo 45.3‐ms rectangular E180 pulses, which had negligible effects 0.15‐ppm away from the carrier frequency, were implemented in a MEGA‐PRESS sequence with TE 139 ms. Three acquisitions were designed to selectively edit lactate and threonine, in which the E180 pulses were tuned to 4.1 ppm, 4.25 ppm, and a frequency far off resonance. Editing performance was validated with numerical analyses and acquisitions from phantoms. The narrow‐band E180 MEGA and another MEGA‐PRESS sequence with broad‐band E180 pulses were evaluated in six healthy subjects.ResultsThe 45.3‐ms E180 MEGA offered a difference‐edited lactate signal with lower intensity and reduced contamination from threonine compared to the broad‐band E180 MEGA. The 45.3 ms E180 pulse had MEGA editing effects over a frequency range larger than seen in the singlet‐resonance inversion profile. Lactate and threonine in healthy brain were both estimated to be 0.4 ± 0.1 mM, with reference to N‐acetylaspartate at 12 mM.ConclusionNarrow‐band E180 MEGA editing minimizes threonine contamination of lactate spectra and may improve the ability to detect modest changes in lactate levels.
Airway Mucus Plugs and Chronic Obstructive Pulmonary Disease Exacerbations
Kim, V., Nath, H.P., Yen, A., Wang, Wei , Orejas, J. , Kligerman, Seth , Jacobs, Kathleen, Espinosa, C. Cano, Estebar, R. San Jose, Manapragada, Padma P. , Abozeed, Mostafa , Terry, Nina , Zahid, Mohd , Sonavane, Sushil, Cho, M.H. , Grumley, Scott , Dolliver, Wojciech Remington , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Díaz, Alejandro A.

Mayo Clinic

B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2858-A2858

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2858 Get It

Persistent Airway Mucus Plugs and Changes in Lung Function in COPD
Mettler, S.K., Nath, H.P., Orejas, J. , Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , DIAZ, ALEJANDRO A, Grumley, Scott , Dolliver, Wojciech Remington , Aziz, Muhammad Usman , Estépar, Raúl San Jośe

Mayo Clinic

B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2857-A2857

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2857 Get It